We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

A Study of Rivoceranib and Trifluridine/Tipiracil for Metastatic Colorectal Cancer (mCRC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04073615
Recruitment Status : Active, not recruiting
First Posted : August 29, 2019
Last Update Posted : May 25, 2022
Information provided by (Responsible Party):
Elevar Therapeutics

Brief Summary:
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of rivoceranib when used in combination with trifluridine/tipiracil in participants with mCRC and to assess progression-free survival (PFS) in participants with mCRC.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: Rivoceranib Drug: Trifluridine/Tipiracil Phase 1 Phase 2

Detailed Description:

This a multicenter open-label study comparing safety, tolerability and efficacy of rivoceranib and trifluridine/tipiracil monotherapies, and the combination of rivoceranib plus trifluridine/tipiracil in participants with mCRC. Participants with histologically or cytologically definitive adenocarcinoma of the colon or rectum who have progressed following standard of care therapy for colorectal cancer (CRC) will be randomly assigned (1:1:2) to rivoceranib, trifluridine/tipiracil or rivoceranib plus trifluridine/tipiracil treatment groups.

The study will consist of an initial phase 1b portion to assess the safety of and determine the RP2D of rivoceranib in combination with trifluridine/tipiracil. A subsequent phase 2 portion will assess the primary endpoint of progression free survival (PFS) by investigator assessment. When a participant discontinues rivoceranib and/or trifluridine/tipiracil for any reason, the participant will enter the 12-month survival follow-up period until withdrawal of consent from the study, lost to follow-up, end of the study or death, whichever occurs earlier.

The maximum duration of the study is estimated to be 36 months, which includes screening, treatment, and follow-up phases.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal Cancer
Actual Study Start Date : November 18, 2019
Estimated Primary Completion Date : April 15, 2023
Estimated Study Completion Date : April 15, 2023

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Rivoceranib
Participants will receive an oral dose of rivoceranib once per day on Days 1 through 28 of each 28-day cycle.
Drug: Rivoceranib
Film-coated tablets
Other Names:
  • Rivoceranib Mesylate
  • Apatinib Mesylate
  • Apatinib

Active Comparator: Trifluridine/tipiracil
Participants will receive an oral dose of Trifluridine/tipiracil twice per day with food, on Days 1 through 5 and Days 8 through 12 of each 28-day cycle.
Drug: Trifluridine/Tipiracil
Film-coated tablets
Other Name: Lonsurf

Experimental: Rivoceranib and trifluridine/tipiracil
Participants will receive a daily oral dose of rivoceranib on Days 1 through 28 and the recommended phase 2 dose (RP2D) of trifluridine/tipiracil twice per day between Days 1 to 5 and 8 to 12 of each 28-day cycle.
Drug: Rivoceranib
Film-coated tablets
Other Names:
  • Rivoceranib Mesylate
  • Apatinib Mesylate
  • Apatinib

Drug: Trifluridine/Tipiracil
Film-coated tablets
Other Name: Lonsurf

Primary Outcome Measures :
  1. (Phase 1b) Percentage of Participants with Dose-limiting Toxicity (DLT) During Cycle 1 [ Time Frame: Baseline up to 28 days ]
  2. (Phase 1b) Number of Participants with Adverse Events (AEs)investigator assessment [ Time Frame: Baseline up to 3 years ]
  3. (Phase 1b) Number of Participants with Serious Adverse Events (SAEs) [ Time Frame: Baseline up to 3 years ]
  4. (Phase 2) Progression Free Survival (PFS) per the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator Assessment [ Time Frame: Up to approximately 3 years ]

Secondary Outcome Measures :
  1. (Phase 1b and Phase 2) Overall Survival (OS) [ Time Frame: Up to approximately 3 years ]
    OS is the time from participant enrollment until death from any cause.

  2. (Phase 2) Objective Response Rate (ORR) [ Time Frame: Up to approximately 3 years ]
    ORR per RECIST v1.1 by Investigator Assessment is defined as percentage of participants who will achieve confirmed Complete Response (CR) or Partial Response (PR).

  3. Duration of Response (DoR) [ Time Frame: Up to approximately 3 years ]
    DoR per RECIST v1.1 by investigator assessment.

  4. Time to Progression (TTP) [ Time Frame: Up to approximately 3 years ]
    TTP per RECIST v1.1 by investigator assessment.

  5. (Phase 2) Disease Control Rate (DCR) [ Time Frame: Up to approximately 3 years ]
    DCR per RECIST v1.1 by investigator assessment.

  6. (Phase 1b and 2) Number of Participants with Adverse Events (AEs) that Worsen in Severity as Defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [ Time Frame: Up to approximately 3 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Histological or cytological confirmation of the diagnosis of mCRC
  2. Failure to respond or be intolerant of at least 2 prior regimens of standard anti-cancer treatments (study treatment must be 3rd-line or greater for mCRC). Failed prior treatments may include:

    • Fluoropyrimidines-based chemotherapy
    • Irinotecan-based chemotherapy
    • Oxaliplatin-based chemotherapy
    • Anti-Vascular Endothelial Growth Factor (VEGF) biological therapy
    • Anti-Epidermal Growth Factor Receptor (EGFR) therapy, if RAS wild-type
    • Immunotherapy (for example, nivolumab, pembrolizumab and ipilimumab), in participants with Microsatellite Instability High/Deficient Mismatch Repair (MSI-H/dMMR). Participants who had received adjuvant chemotherapy and had recurrence during or within 6 months of completion of the adjuvant chemotherapy would be considered as 1 prior line of therapy
  3. Have progressed based on imaging during or within 3 months of the last administration of most recent therapy
  4. Have measurable disease, as defined by RECIST v1.1
  5. Adequate bone marrow, renal, and hepatic function, as evidenced by the following within 7 days prior to Cycle 1 Day 1

    • Absolute neutrophil count (ANC) ≥1,500/mm3
    • Platelets ≥75,000/mm3
    • Hemoglobin ≥9.0 g/dL
    • Creatinine clearance (according to Cockcroft-Gault Equation or by 24 hr urine collection) > 50 mL/min and serum creatinine <1.0× upper limit of normal (ULN)
    • Aspartate transaminase (AST) and alanine transaminase (ALT) ≤3.0x ULN (≤5.0 × ULN for participants with liver involvement of their cancer)
    • Bilirubin ≤1.5 × ULN
    • Alkaline phosphatase ≤2.5 × ULN (≤5 × ULN with liver involvement of their cancer)
    • International normalized ratio (INR) / partial thromboplastin time (PTT) ≤1.5 × ULN (Participants currently under treatment with anti-thrombotic agents such as warfarin or heparin with no abnormal coagulation values can participate in this study)
  6. Urinary protein <2+ on dipstick or routine urinalysis. If urine dipstick or routine analysis indicates proteinuria ≥ 2+, a 24-hour urine or urine protein/creatinine ratio must be collected and must demonstrate <2 g of protein in 24 hours to allow participation in the study.
  7. Have an Eastern Cooperative Oncology Group (ECOG) status of 0 or 1

Exclusion Criteria:

  1. Prior treatment with rivoceranib or trifluridine/tipiracil
  2. Prior treatment with other VEGFR small molecule inhibitors (for example, regorafenib)
  3. Packed red blood cell transfusion or erythropoietin therapy within 14 days prior to first dose of study drug
  4. History of another malignancy within 3 years prior to Cycle 1 Day 1. A participant with the following malignancies is eligible for this study if, in the opinion of the Investigator, they do not pose a significant risk to life expectancy:

    • Carcinoma of the skin without melanomatous features
    • Curatively treated cervical carcinoma in situ
    • Bladder tumors considered superficial such as noninvasive (T1a) and carcinoma in situ (Tis)
    • Thyroid papillary cancer with prior treatment
    • Prostate cancer which has been surgically or medically treated and not likely to recur within 3 years

6. Active renal dysfunction that requires dialysis treatments

7. Active cardiac disease including any of the following:

  • Congestive heart failure New York Heart Association (NYHA) ≥Class 2
  • Myocardial infarction less than 6 months before the start of Cycle 1 Day 1 of treatment

    8. Cardiac arrhythmias requiring antiarrhythmic therapy (beta-blockers or digoxin are permitted)

    9. History of uncontrolled hypertension (blood pressure ≥140/90 mmHg and/or change in antihypertensive medication within 7 days prior to first dose of study drug)

    10. History of antiangiogenic drug class-related severe adverse reactions, including uncontrolled hypertension or others related to prior therapy discontinuation and/or those that may indicate a higher risk to a participant' safety, in the Investigator's opinion, if provided further antiangiogenic treatment.

    11. History of vascular disease including arterial or venous embolic events (pulmonary embolism), other than hypertension, within 6 months prior to Cycle 1 Day 1 (for example, hypertensive crisis, hypertensive encephalopathy, stroke or transient ischemic attack [TIA], or significant peripheral vascular diseases) that, in the Investigator's opinion, may pose a risk to the participant on VEGF inhibitor therapy.

    12. History of clinically significant thrombosis within 3 months prior to first dose of study drug that, in the Investigator's opinion, may place the participant at risk of side effects from antiangiogenics medications

    13. History of bleeding diathesis or clinically significant bleeding within 14 days prior to first dose of study drug

    14. Therapy with systemic anticoagulant or antithrombotic agents within 7 days prior to first dose of study drug that in the Investigator's opinion could interfere with clotting. The maximum allowable daily dose of aspirin is 325 milligram (mg).

    15. Participants with unstable seizure disorder requiring medication changes within 3 months of Cycle 1 Day 1 treatment

    16. Untreated or active central nervous system (CNS) or leptomeningeal metastases. Participants are eligible if metastases have been treated and participants are neurologically returned to baseline or neurologically stable (expect for residual signs and symptoms related to the CNS treatment) for at least 4 weeks prior to first dose of study drug. In addition, participants must be either off corticosteroids, or on a stable dose or decreasing dose of ≤ 20 mg daily prednisone or prednisone-equivalent. A baseline radiological assessment of the brain will be performed on participants who have prior history of metastases with CNS involvement

    17. History of clinically significant glomerulonephritis, biopsy-proven nephritis, crystal nephropathy or other renal insufficiencies

    18. Unresolved adverse reactions >Grade 1 excluding peripheral neuropathy or treatment related myelosuppression

    19. Known hypersensitivity to any of the study drugs, study drug classes, or any components of study drug formulations

    20. Inability to swallow oral medications

    21. An active malabsorption condition, or any other condition that in the opinion of the Investigator might affect the absorption of study drug

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04073615

Layout table for location information
United States, Florida
Florida Cancer Specialists
Sarasota, Florida, United States, 34232
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, Tennessee
Vanderbilt University School of Medicine
Nashville, Tennessee, United States, 37232
Sponsors and Collaborators
Elevar Therapeutics
Layout table for additonal information
Responsible Party: Elevar Therapeutics
ClinicalTrials.gov Identifier: NCT04073615    
Other Study ID Numbers: RM-110
First Posted: August 29, 2019    Key Record Dates
Last Update Posted: May 25, 2022
Last Verified: May 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents